Kalium Health, a digital health spin-out from the University of Cambridge, aims to transform the management of cardiorenal diseases with real-time blood electrolyte data.
We assisted Kalium on their most recent investment round that will fund advancements in their health technology, driving the development of blood monitoring tech for those living with chronic kidney or heart diseases. This new round means further growth for Kalium Health in the form of new laboratories and recruitment of talented scientists, engineers and support staff.
Kalium Health’s roots are firmly planted in Cambridge, being a University of Cambridge spin-out company. Their journey began with grant funding from, notably, Kidney Research UK, since when they have secured two rounds of investment and structured the company for rapid growth.
Callum Blundell, associate at Taylor Vinters, said: “Many congratulations to Tom and the team at Kalium Health! It was an absolute delight to work on the company’s most recent investment round and we wish them continued success in the future working on such crucial and life-changing innovations.”
Tom Collings, CEO, Kalium Health commented: “The support we have received from Callum and the Emerging Companies team has been second to none. Their speed of response and thoroughness, combined with their considerable expertise, contributed to an efficient process that meant I could maintain my focus on growing the company. As we negotiate commercial partnerships and plan for further investment, I know I can count on Taylor Vinters.”
